← All Sponsors
SPONSOR

Virogin Biotech Canada Ltd

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Hepatocellular CarcinomaIntrahepatic Cholangiocarcinoma
NCT05223816 Phase 2
Recruiting

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Hepatocellular Carcinoma
United States View Trial →